Literature DB >> 27519341

Trovafloxacin : A Viewpoint by Keith P. Klugman.

K P Klugman1.   

Abstract

Entities:  

Year:  1997        PMID： 27519341     DOI： 10.2165/00003495-199754030-00007

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  2 in total

1.  The clinical relevance of in-vitro resistance to penicillin, ampicillin, amoxycillin and alternative agents, for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.

Authors:  K P Klugman
Journal:  J Antimicrob Chemother       Date:  1996-07       Impact factor: 5.790

2.  Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.

Authors:  T D Gootz; R Zaniewski; S Haskell; B Schmieder; J Tankovic; D Girard; P Courvalin; R J Polzer
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.